Aggregated News

Geron has quit on embryonic stem cells. The company is abandoning its world-leading clinical trial, aimed at using stem cells to treat people paralyzed with spinal-cord injuries. It is laying off more than a third of its staff, and is writing off about $8 million. It has also repaid the California Institute of Regenerative Medicine (CIRM) a loan of more than $6 million, plus interest. Geron will continue to monitor the four patients currently enrolled in the phase 1 clinical trial, and says it is looking for another company to take it over.

The decision to terminate the trial seems to be all business, a departure from past practices that seemed motivated more by hype and wishful thinking. Geron's stock has been plummeting (down from $6.34 to $1.60 over the year), and new management is conducting triage. The ESC trial is only in phase 1, a safety trial, in which severely injured patients receive low doses of treatments that are frankly unlikely to do much good; the point is to ensure that they do no harm. Results from that...

Technologies